BMRN vs. ALNY, BIIB, UTHR, INCY, NBIX, EXEL, RGEN, EXAS, HALO, and MDGL
Should you be buying BioMarin Pharmaceutical stock or one of its competitors? The main competitors of BioMarin Pharmaceutical include Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), United Therapeutics (UTHR), Incyte (INCY), Neurocrine Biosciences (NBIX), Exelixis (EXEL), Repligen (RGEN), Exact Sciences (EXAS), Halozyme Therapeutics (HALO), and Madrigal Pharmaceuticals (MDGL). These companies are all part of the "biotechnology" industry.
BioMarin Pharmaceutical vs.
Alnylam Pharmaceuticals (NASDAQ:ALNY) and BioMarin Pharmaceutical (NASDAQ:BMRN) are both large-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, dividends, media sentiment, community ranking, institutional ownership, valuation, risk, analyst recommendations and earnings.
In the previous week, Alnylam Pharmaceuticals had 29 more articles in the media than BioMarin Pharmaceutical. MarketBeat recorded 55 mentions for Alnylam Pharmaceuticals and 26 mentions for BioMarin Pharmaceutical. BioMarin Pharmaceutical's average media sentiment score of 0.85 beat Alnylam Pharmaceuticals' score of 0.69 indicating that BioMarin Pharmaceutical is being referred to more favorably in the news media.
93.0% of Alnylam Pharmaceuticals shares are owned by institutional investors. Comparatively, 98.7% of BioMarin Pharmaceutical shares are owned by institutional investors. 1.5% of Alnylam Pharmaceuticals shares are owned by insiders. Comparatively, 1.9% of BioMarin Pharmaceutical shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
BioMarin Pharmaceutical has a net margin of 14.96% compared to Alnylam Pharmaceuticals' net margin of -12.37%. BioMarin Pharmaceutical's return on equity of 9.91% beat Alnylam Pharmaceuticals' return on equity.
Alnylam Pharmaceuticals currently has a consensus price target of $312.30, indicating a potential upside of 7.43%. BioMarin Pharmaceutical has a consensus price target of $94.00, indicating a potential upside of 30.57%. Given BioMarin Pharmaceutical's higher probable upside, analysts clearly believe BioMarin Pharmaceutical is more favorable than Alnylam Pharmaceuticals.
Alnylam Pharmaceuticals has a beta of 0.39, meaning that its stock price is 61% less volatile than the S&P 500. Comparatively, BioMarin Pharmaceutical has a beta of 0.33, meaning that its stock price is 67% less volatile than the S&P 500.
BioMarin Pharmaceutical received 419 more outperform votes than Alnylam Pharmaceuticals when rated by MarketBeat users. However, 76.28% of users gave Alnylam Pharmaceuticals an outperform vote while only 74.56% of users gave BioMarin Pharmaceutical an outperform vote.
BioMarin Pharmaceutical has higher revenue and earnings than Alnylam Pharmaceuticals. Alnylam Pharmaceuticals is trading at a lower price-to-earnings ratio than BioMarin Pharmaceutical, indicating that it is currently the more affordable of the two stocks.
Summary
BioMarin Pharmaceutical beats Alnylam Pharmaceuticals on 12 of the 18 factors compared between the two stocks.
Get BioMarin Pharmaceutical News Delivered to You Automatically
Sign up to receive the latest news and ratings for BMRN and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
BioMarin Pharmaceutical Competitors List
Related Companies and Tools
This page (NASDAQ:BMRN) was last updated on 3/25/2025 by MarketBeat.com Staff
Buy BMRN Stock Free BMRN Stock Alerts